TABLE 1.
Demographic and Clinical Characteristics
| All Patients (N = 2,100) | Men (n = 1,493) | Women (n = 607) | |
|---|---|---|---|
| Age, yrs | 59 (36–78) | 60 (39–79) | 57 (34–78) |
| Race* | |||
| Black | 705 (34) | 420 (28) | 285 (47) |
| White | 1,251 (60) | 970 (65) | 281 (46) |
| Other | 113 (5) | 84 (6) | 29 (2) |
| NYHA class | |||
| II | 1,338 (64) | 960 (64) | 378 (62) |
| III/IV | 762 (36) | 533 (36) | 229 (38) |
| Ischemic etiology | 1,060 (50) | 873 (58) | 187 (31) |
| Left ventricular ejection fraction, % | 25 (14–37) | 24 (14–36) | 25 (13–39) |
| Atrial fibrillation | 441 (21) | 371 (25) | 70 (12) |
| Diabetes | 681 (32) | 504 (34) | 177 (29) |
| Hypertension* | 1,270 (61) | 922 (62) | 348 (58) |
| Systolic blood pressure, mm Hg | 112 (88–146) | 111 (90–146) | 112 (86–148) |
| Diastolic blood pressure, mm Hg | 70 (54–90) | 70 (54–90) | 70 (54–90) |
| Heart rate, beats·min−1 | 70 (54–92) | 70 (54–90) | 71 (54–88) |
| Blood urea nitrogen, mg/dl−1 | 20 (10–49) | 21 (11–53) | 17 (9–43) |
| Creatinine, mg/dl−1 | 1.2 (0.8–2.1) | 1.2 (0.8–2.2) | 1.0 (0.7–1.8) |
| Medications and devices | |||
| ACEI or ARB | 1,982 (94) | 1,408 (94) | 574 (95) |
| Beta-adrenergic blocking agent | 1,980 (94) | 1,408 (94) | 572 (94) |
| Aldosterone receptor antagonist | 935 (45) | 647 (43) | 288 (47) |
| Loop diuretic | 1,628 (78) | 1,165 (78) | 463 (76) |
| Biventricular pacemaker | 373 (18) | 291 (19) | 82 (14) |
Values are median (5th–95th percentiles) or n (%).
*
Indicates the number of patients (%) with nonmissing data.
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; NYHA = New York Heart Association.